A joint statement from the National Kidney Foundation and the American Society of Nephrology
July 2, 2020
Of the more than 37 million people affected by kidney diseases in the United States, a disproportionate number are of African American, Hispanic, Asian, and Native American descent. African Americans are three times more likely than Non-Hispanic Whites to experience kidney failure. Such disparities go beyond the high...
Poster presentations shared with thousands at virtual NKF 2021 Spring Clinical Meetings
April 8, 2021—New York, NY — Thousands of kidney disease professionals gathered virtually this week for the National Kidney Foundation’s 2021 Spring Clinical Meetings to exchange knowledge, honor the dedication of those in the community, and share cutting-edge research on kidney...
Late-breaking presentations shared before thousands at virtual NKF’s 2021 Spring Clinical Meetings
April 7, 2021—New York, NY — Today, before the National Kidney Foundation’s 2021 Spring Clinicals Meetings of thousands of kidney health professionals, hundreds of studies from the last year were presented including...
Tool will help doctors assess childhood kidney disease
Feb. 9, 2020, New York, NY — Today, the National Kidney Foundation (NKF) unveiled a new clinical tool for pediatric healthcare professionals to assess kidney disease progression in children and help provide more targeted care.
Kidney disease is rare in children in the...
A joint statement from the National Kidney Foundation and the American Society of Nephrology December 17, 2020
On behalf of the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN), we thank the trainees, clinicians, and the public—particularly people with kidney diseases, kidney failure, and kidney transplants—for their ongoing support of the ...
Largest Compilation of Kidney Data Ever Collected is Analyzed and Presented at Joint Scientific Workshop
Silver Spring, MD—March 16, 2018—Today, the National Kidney Foundation (NKF), along with the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) concluded a scientific workshop collaboration to review the results of a major, multi-year meta-analysis examining the largest compilation of data ever collected on...
Study was joint effort of the National Kidney Foundation, the U.S. Food and Drug Administration and the European Medicines Agency
New York, NY – August 28, 2019 - The American Journal of Kidney Diseases (AJKD) will publish today an article summarizing the deliberations and recommendations from a Scientific Workshop that was a joint effort of the National Kidney Foundation (NKF), the Food and...
The National Kidney Foundation Statement about INVOKANA® (Canagliflozin)
New York, NY–Sept. 30, 2019— “The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that their drug INVOKANA® (Canagliflozin) has been approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 diabetes and chronic kidney disease (...
Paper cites reasons including physicians’ high workloads and electronic health record design as key challenges to patients getting timely follow-up tests
New York, NY - July 16, 2019 – A team of investigators studied electronic medical data on more than 200,000 of adults and found that 58 percent of patients with a newly abnormal estimated glomerular filtration rate (eGFR) were not getting timely follow-up testing after...
National Kidney Foundation and CareFirst partnered for the first time on landmark study
New York, NY – November 12, 2019 - A new study conducted by the National Kidney Foundation and CareFirst BlueCross BlueShield (CareFirst) found that detecting chronic kidney disease (CKD) with two...
